Systems biology of IL-6, IL-12 family cytokines.

A. Dittrich,W. Hessenkemper,F. Schaper

DOI: https://doi.org/10.1016/j.cytogfr.2015.07.002

IF: 17.66

2015-10-01

Cytokine & Growth Factor Reviews

Abstract:

What problem does this paper attempt to address?

Adjuvant immunotherapy for melanoma patients: progress and opportunities

T.A. Sussman,P.A. Ott

DOI: https://doi.org/10.1016/j.esmoop.2024.102962

IF: 6.883

2024-04-19

ESMO Open

Abstract:The immunotherapeutic treatment landscape for patients with high-risk melanoma has increased in complexity at a rapid pace. Neoadjuvant immunotherapy has an increasingly important role in patients with high-risk surgically resectable melanoma. Identifying the most effective therapeutic regimen in the adjuvant setting will require additional randomized studies. Novel checkpoint inhibitors, personalized vaccines, and better predictive tools are on the horizon. The majority of patients who are diagnosed with cutaneous melanoma are candidates for surgical resection and thus curable from their disease. However, the risk for a recurrence is high for many patients, including those with lymph node-negative melanoma, thus necessitating additional therapies beyond surgery. With the advent of anti-programmed cell death protein 1 (PD-1)-based immunotherapies, which are vastly more effective compared to previous standard-of-care treatments in the advanced setting, the landscape of adjuvant therapy has fundamentally changed in recent years. Anti-PD-1-based immune checkpoint inhibition therapy is now the standard of care for many patients with stage IIB or higher melanoma. Neoadjuvant approaches have demonstrated superior outcomes compared to adjuvant-alone therapy. However, a number of questions remain including treatment combinations such as combined anti-PD-1 + lymphocyte activation gene-3, optimal sequencing of therapies, and the use of predictive markers to further improve outcomes for patients with high-risk melanoma.

oncology
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Islam Eljilany,Ella Castellano,Ahmad A Tarhini

DOI: https://doi.org/10.3390/cancers15164125

2023-08-16

Abstract:The consideration of systemic adjuvant therapy is recommended for patients with stage IIB-IV melanoma who have undergone surgical resection due to a heightened risk of experiencing melanoma relapse and mortality from melanoma. Adjuvant therapy options tested over the past three decades include high-dose interferon-α, immune checkpoint inhibitors (pembrolizumab, nivolumab), targeted therapy (dabrafenib-trametinib for BRAF mutant melanoma), radiotherapy and chemotherapy. Most of these therapies have been demonstrated to enhance relapse-free survival (RFS) but with limited to no impact on overall survival (OS), as reported in randomized trials. In contemporary clinical practice, the adjuvant treatment approach for surgically resected stage III-IV melanoma has undergone a notable shift towards the utilization of nivolumab, pembrolizumab, and BRAF-MEK inhibitors, such as dabrafenib plus trametinib (specifically for BRAF mutant melanoma) due to the significant enhancements in RFS observed with these treatments. Pembrolizumab has obtained regulatory approval in the United States to treat resected stage IIB-IIC melanoma, while nivolumab is currently under review for the same indication. This review comprehensively analyzes completed phase III adjuvant therapy trials in adjuvant therapy. Additionally, it provides a summary of ongoing trials and an overview of the main challenges and future directions with adjuvant therapy.
Changing the Future As We Prepare for a New Millennium

J. Fain

DOI: https://doi.org/10.1177/014572179902500501

1999-09-01

The Diabetes Educator

Abstract:
ORGANO-NITROGEN COMPOUNDS FROM MOLECULAR NITROGEN

J. Delcamp

Abstract:INTRODUCTION Industrial nitrogen fixation plays an important role in sustaining approximately 40% of the Earth’s population through generation of synthetic fertilizers. Annually, ca. 500 million tons of anhydrous ammonia, ammonium nitrate, and urea are produced through the Haber-Bosch process, which requires harsh conditions (200 atm, 450-500C) and affords low yields 10-20%. It has been estimated that this accounts for 1% of the world’s annual energy consumption. An efficient, mild method for fixating molecular nitrogen would be of great worth not only due to the immediate energy savings but it would also serve to provide novel reactivity possibly capable of generating organo-nitrogen compounds from molecular nitrogen. The first, stable dinitrogen coordination complex, [Ru(NH3)5(N2)], was isolated in 1965 by Allen and Senoff, and this initial observation has led to the development of many systems (primarily based on molybdenum, tungsten, and titanium) for incorporating molecular nitrogen into organic molecules. This review will focus on the various methods for generation of nitrogen-containing organic molecules based on synthetic nitrogen fixation processes. Background Thermodynamically, the fixation of nitrogen is an exothermic process for both protonation and hydrogenation steps (Scheme 1). However, as is evident from the hydrogenation of N2 to N2H2, the
Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Ankit Patel,Joseph Skitzki

DOI: https://doi.org/10.1002/jso.26746

2021-12-13

Journal of Surgical Oncology

Abstract:Adjuvant systemic therapy for cutaneous melanoma has experienced practice-changing shifts over the last decade. The successful results of immunotherapies and targeted therapies in the metastatic setting have allowed for investigative trials of the same therapies in the adjuvant and now neoadjuvant setting, with the potential for improved clinical outcomes in patients with high risk resected Stage III and IV melanoma.

oncology,surgery
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Ryan C. Augustin,Jason J. Luke

DOI: https://doi.org/10.1007/s40257-024-00852-5

2024-02-28

American Journal of Clinical Dermatology

Abstract:With the development of effective BRAF -targeted and immune-checkpoint immunotherapies for metastatic melanoma, clinical trials are moving these treatments into earlier adjuvant and perioperative settings. BRAF -targeted therapy is a standard of care in resected stage III–IV melanoma, while anti-programmed death-1 (PD1) immunotherapy is now a standard of care option in resected stage IIB through IV disease. With both modalities, recurrence-free survival and distant-metastasis-free survival are improved by a relative 35–50%, yet no improvement in overall survival has been demonstrated. Neoadjuvant anti-PD1 therapy improves event-free survival by approximately an absolute 23%, although improvements in overall survival have yet to be demonstrated. Understanding which patients are most likely to recur and which are most likely to benefit from treatment is now the highest priority question in the field. Biomarker analyses, such as gene expression profiling of the primary lesion and circulating DNA, are preliminarily exciting as potential biomarkers, though each has drawbacks. As in the setting of metastatic disease, markers that inform positive outcomes include interferon- γ gene expression, PD-L1, and high tumor mutational burden, while negative predictors of outcome include circulating factors such as lactate dehydrogenase, interleukin-8, and C-reactive protein. Integrating and validating these markers into clinically relevant models is thus a high priority. Melanoma therapeutics continues to advance with combination adjuvant approaches now investigating anti-PD1 with lymphocyte activation gene 3 (LAG3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and individualized neoantigen therapies. How this progress will be integrated into the management of a unique patient to reduce recurrence, limit toxicity, and avoid over-treatment will dominate clinical research and patient care over the next decade.

dermatology
The Relation between Five-Factor Personality Traits and Risk-Taking Behavior in Preadolescents

Ron Mcghee,David J. Ehrler,J. Buckhalt,C. Phillips

DOI: https://doi.org/10.4236/PSYCH.2012.38083

2012-08-23

Abstract:The predictive relation between Five-Factor Model (FFM) personality traits using the Five Factor Personality Inventory-Children (FFPI-C) and degrees of risk-taking in preadolescents (ages 10 to 12) was studied in a sample of 50 fifth-graders. Results indicated that high Extraversion and Openness to Experience and low Conscientiousness were correlated with high risk-taking. The FFPI-C factors were significantly predictive of risk-taking behavior, and accounted for 42% of the risk-taking variance, based on a multiple regression analysis. These findings suggest that the same mechanisms that are associated with adult risk-taking may already be present in children as young as 10 to 12-years of age.
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care

Kylie A. Fletcher,Douglas B. Johnson

DOI: https://doi.org/10.1097/ppo.0000000000000702

2024-03-27

The Cancer Journal

Abstract:The advent of effective immunotherapy, specifically cytotoxic T-lymphocyte associated protein 4 and programmed cell death 1 inhibitors, as well as targeted therapy including BRAF/MEK inhibitors, has dramatically changed the prognosis for metastatic melanoma patients. Up to 50% of patients may experience long-term survival currently. Despite these advances in melanoma treatment, many patients still progress and die of their disease. As such, there are many studies aimed at providing new treatment options for this population. Therapies currently under investigation include, but are not limited to, novel immunotherapies, targeted therapies, tumor-infiltrating lymphocytes and other cellular therapies, oncolytic viral therapy and other injectables, and fecal microbiota transplant. In this review, we discuss the emerging treatment options for metastatic melanoma patients who have progressed on standard of care treatments.

oncology
Current Advances in the Treatment of BRAF-Mutant Melanoma

Hima Patel,Nour Yacoub,Rosalin Mishra,Aaron White,Long Yuan,Samar Alanazi,Joan T. Garrett

DOI: https://doi.org/10.3390/cancers12020482

2020-02-19

Cancers

Abstract:Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15–20% before the advent of immunotherapy. Treatment with immune checkpoint inhibitors has increased long-term survival outcomes in patients with advanced melanoma to as high as 50% although individual response can vary greatly. A mutation within the MAPK pathway leads to uncontrollable growth and ultimately develops into cancer. The most common driver mutation that leads to this characteristic overactivation in the MAPK pathway is the B-RAF mutation. Current combinations of BRAF and MEK inhibitors that have demonstrated improved patient outcomes include dabrafenib with trametinib, vemurafenib with cobimetinib or encorafenib with binimetinib. Treatment with BRAF and MEK inhibitors has met challenges as patient responses began to drop due to the development of resistance to these inhibitors which paved the way for development of immunotherapies and other small molecule inhibitor approaches to address this. Resistance to these inhibitors continues to push the need to expand our understanding of novel mechanisms of resistance associated with treatment therapies. This review focuses on the current landscape of how resistance occurs with the chronic use of BRAF and MEK inhibitors in BRAF-mutant melanoma and progress made in the fields of immunotherapies and other small molecules when used alone or in combination with BRAF and MEK inhibitors to delay or circumvent the onset of resistance for patients with stage III/IV BRAF mutant melanoma.

oncology
Neoadjuvant therapy for resectable melanoma

Cimarron E. Sharon,Giorgos C. Karakousis

DOI: https://doi.org/10.1007/s10585-023-10263-1

2024-01-29

Clinical & Experimental Metastasis

Abstract:The standard of care for patients with resectable stage III/IV melanoma classically included upfront resection with adjuvant therapy. However, in more recent years, the amount of systemic therapies available for neoadjuvant use for these patients has increased. This article reviewed clinical trials investigating neoadjuvant therapy for patients with resectable stage III/IV melanoma. The outcomes of these trials have identified optimal treatment regimens to maximise patient response and minimize toxicities. Additionally, the date demonstrate advantages to neoadjuvant treatment compared to adjuvant therapy alone. Further research is needed to utilize a patient's response to neoadjuvant treatment for prognostication and creation of an individualized treatment plan.

oncology
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Ahmad A. Tarhini,Ella Castellano,Islam Eljilany

DOI: https://doi.org/10.1097/ppo.0000000000000706

2024-03-27

The Cancer Journal

Abstract:Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti–cytotoxic T-lymphocyte antigen 4 ipilimumab at 10 mg/kg compared with placebo and ipilimumab 3 mg/kg compared with high-dose interferon α. In the modern era, more recent phase III trials demonstrated significant recurrence-free survival improvements with anti–programmed cell death protein 1, pembrolizumab, and BRAF-MEK inhibitor combination dabrafenib-trametinib (for BRAF mutant melanoma) versus placebo. Furthermore, anti–programmed cell death protein 1, nivolumab and pembrolizumab have both been shown to significantly improve recurrence-free survival as compared with ipilimumab 10 mg/kg. For melanoma patients with clinically or radiologically detectable locoregionally advanced disease, emerging data support an important role for preoperative systemic neoadjuvant therapy. Importantly, a recent cooperative group trial (S1801) reported superior event-free survival rates with neoadjuvant versus adjuvant therapy. Collectively, current data from neoadjuvant immunotherapy and targeted therapy trials support a future change in clinical practice in favor of neoadjuvant therapy for eligible melanoma patients.

oncology
Precision Oncology in Melanoma: Changing Practices

Sean C. Dougherty,William L. Flowers,Elizabeth M. Gaughan

DOI: https://doi.org/10.2967/jnumed.124.267781

2024-12-04

Journal of Nuclear Medicine

Abstract:Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis for metastatic melanoma was poor because of limited treatment options. However, after multiple landmark clinical trials displaying the efficacy of combined BRAF/MEK inhibition for BRAF -mutant melanoma and the application of immune checkpoint inhibitors targeting the programmed death-1, cytotoxic T-lymphocyte antigen-4, and lymphocyte activation gene-3 molecules, overall survival rates have dramatically improved. The role of immune checkpoint inhibition has since expanded to the neoadjuvant and adjuvant settings with multiple regimens in routine use. Personalized therapies, including tumor-infiltrating lymphocytes that are extracted from a patient's melanoma and eventually reinfused into the patient, and messenger RNA vaccines used to target neoantigens unique to a patient's tumor, show promise. Improvements in accompanying imaging modalities, particularly within the field of nuclear medicine, have allowed for more accurate staging of disease and assessment of treatment response. Continued growth in the role of nuclear medicine in the evaluation of melanoma, including the incorporation of artificial intelligence into image interpretation and use of radiolabeled tracers allowing for intricate imaging of the tumor immune microenvironment, is expected in the coming years.

radiology, nuclear medicine & medical imaging
Therapeutic options in cutaneous melanoma: latest developments

Rodabe N. Amaria,Karl D. Lewis,Rene Gonzalez

DOI: https://doi.org/10.1177/1758834011415308

2011-07-22

Therapeutic Advances in Medical Oncology

Abstract:Melanoma is a malignancy that is highly curable in the early stages but has devastating consequences in later stages due to lack of response to traditional treatments. Improved understanding of the basic science of tumorigenesis has helped lead to novel targeted therapies which are producing beneficial results in patients with melanoma. Enhancement of the immune system by blockade of the cytotoxic T-lymphocyte associated antigen-4 by the monoclonal antibody ipilimumab is now approved by the United States Food and Drug Administration (FDA) for use in patients with unresectable melanoma. The approval of this drug was based on the first ever data in melanoma showing an improvement in overall survival. New advances in targeting components of the mitogen-activated protein kinase pathway are showing impressive responses in clinical trials in most patients harboring activating mutations in BRAF. Thus, this is a new era in the management of melanoma and we review the recent progress made in treating patients with advanced disease.

oncology
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Russell G. Witt,Derek J. Erstad,Jennifer A. Wargo

DOI: https://doi.org/10.1177/17588359221083052

2022-01-01

Therapeutic Advances in Medical Oncology

Abstract:The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survival with these new treatments, there exists a large portion of patients with surgically resectable disease that are high risk for relapse. Patients with high-risk resectable melanoma account for up to 20% of newly diagnosed cases. For this high-risk group of patients, neoadjuvant therapy has many purposed advantages over adjuvant therapy, including a more robust immune response due to abundant tumor antigens at treatment initiation, the ability to assess pathologic response to therapy, tumor downstaging leading to increased disease resectability, and a potential decreased need for extensive lymphadenectomies. These findings have been backed by preclinical models and multiple neoadjuvant trials are underway. In this review, we will discuss the trials that have set the foundation for the current treatment standards and discuss the role and rationale for neoadjuvant therapy for high-risk malignant melanomas.

oncology
Advances in the discovery and development of melanoma drug therapies

Monica Chanda,Mark S. Cohen

DOI: https://doi.org/10.1080/17460441.2021.1942834

2021-07-19

Expert Opinion on Drug Discovery

Abstract:<span>Therapeutic strategies for melanoma have evolved significantly over the last decade shifting from cytotoxic chemotherapies like dacarbazine to targeted therapies and immunotherapies including immune checkpoint inhibitors. These new drug therapies have improved overall as well as progression-free survival, lowering the mortality of this cancer for melanoma patients with advanced disease. Newer strategies incorporate combination therapies that harness synergies between mechanisms of anticancer efficacy as well as help overcome resistance issues of monotherapies, which remain a challenge.This review looks at each class of drug therapy for melanoma and provides an overview of the preclinical mechanism of action, the clinical efficacy data, and their applications in combination therapy regimens. NCCN treatment guidelines, safety, toxicity, and immune-related adverse events are also described as well as a note on cost.Numerous ongoing trials continue to evaluate the role of novel therapies and combinations for this challenging disease and understanding their mechanism of action, risks, benefits, and treatment guidelines can help care providers and patients have a more comprehensive and tailored discussion of treatment options and expectations.</span>

pharmacology & pharmacy
Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View

Allison Betof-Warner,Ryan J Sullivan,Amod Sarnaik

DOI: https://doi.org/10.1200/EDBK_351114

Abstract:Over the past four decades, cancer immunotherapy for melanoma has evolved from single-agent, type-I cytokine therapy to combination immune checkpoint inhibition. Along the way, breakthroughs in the fields of cell therapy and cancer vaccination have been made as well. The early data from adoptive cell therapy, involving the delivery of tumor infiltrating lymphocytes harvested from resected tumors, was generated at the National Cancer Institute. Subsequently, a limited number of centers across the globe have developed programs to deliver these therapies. Recently, more widespread availability of this therapy has been made possible by centralizing the growth and expansion of tumor infiltrating lymphocyte products, then distributing the products for delivery of therapy at numerous academic medical centers. Work is ongoing to optimize these treatments with additional cell types and/or modified cell products, and to determine the best ways of combining these treatments with immune checkpoint inhibition. Similarly, tumor vaccination strategies are undergoing dramatic changes, transitioning the field from peptide-based vaccines to next-generation sequencing and T-cell receptor sequencing. These changes help improve the selection of targeted antigens by finding more immunogenic options, and they help with the development of lipid nanoparticles and mRNA delivery. In short, evolution of the approaches that are revolutionizing infectious disease vaccination has been ongoing, and there are promising preliminary data in patients with melanoma.
Neoadjuvant Therapy in Advanced Melanoma.

Shalana O'Brien,Jimson Dsouza,Shirly Shohat,Neha Goel,Sanjay S. Reddy,Anthony J. Olszanski,Sujana Movva,Hong Wu,Jian Qin Yu,Miriam Lango,Jeffrey M. Farma

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e21555

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e21555 Background: Treatment paradigms in advanced melanoma are evolving with the success of new targeted and immunotherapies. The purpose of this study is to explore the outcomes associated with neoadjuvant therapy for advanced melanoma at our institution. Methods: We performed a retrospective analysis of all patients diagnosed with melanoma who received neoadjuvant immunotherapy for locally and regionally advanced primary or recurrent disease at an NCI-designated Comprehensive Cancer Center. Demographic information, primary tumor staging and characteristics, treatment regimen, clinical and pathological responses, and radiologic reports were collected. Results: The analytic cohort consisted of 14 patients who either completed or are receiving neoadjuvant immunotherapy. 11 have a cutaneous primary and 3 have an unknown primary. Treatment regimens consisted of PD-1 inhibitor (n = 9), TVEC (n = 1), combination of PD-1 inhibitor and TVEC (n = 3) and combination of CCR2 and PD-1 inhibitors (n = 1). Prior therapy included Ipilimumab in 3 patients and radiation in 2 patients. 5 patients received neoadjuvant therapy for primary disease and 9 patients received neoadjuvant therapy for recurrent disease. 7 patients had overall clinical response (5 complete response (CR), 2 partial response (PR)), 3 patients had stable disease (SD) and 3 patients had progression. 8 patients underwent surgical resection after therapy, 4 of these patients had clinically SD, 1 patient had a PR and 3 patients had progression. Surgeries performed included excision of 2 primary and 2 recurrent sites, 5 lymph node dissections and 1 resection of in-transit disease. Median time to surgery from the start of immunotherapy was 7.5 months (range 0 - 14). 5 patients had a partial and 3 patients had a complete pathological response. 2 patients continued therapy after resection. An additional 6 patients are currently receiving immunotherapy with intent to undergo resection. Median follow-up time from diagnosis was 27 months (range 10 - 95). Conclusions: At our tertiary referral center select patients with locally and regionally advanced melanoma are considered for neoadjuvant immunotherapy with an overall response in 50% of patients. Further studies are currently pending which will likely validate our results.
Dynamical Jahn-Teller effect and fluorescence line narrowing of the 4A2-4T2 zero-phonon transition in KZnF3:Cr.

Pilla,Galvanetto,Montagna,Viliani

DOI: https://doi.org/10.1103/PHYSREVB.38.3477

1988-08-15

Abstract:
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Christy Los,Sebastian Klobuch,John B. A. G. Haanen

DOI: https://doi.org/10.1097/ppo.0000000000000705

2024-03-27

The Cancer Journal

Abstract:Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing patients, their prognosis is still dismal. Based on clinical trial data, treatment with adoptive cell therapies holds great promise. In patients with metastatic melanoma progressing on or nonresponsive to single-agent anti–programmed cell death 1, infusion of tumor-infiltrating lymphocytes can produce responses in up to half of patients, with durable complete responses in up to 20%. Genetic modification of peripheral blood T cells with T-cell receptors derived from tumor-specific T cells, or with chimeric antigen receptors, has the potential to further improve treatment outcomes in this refractory population. In this review, we will discuss the historical development, current status, and future perspectives of adoptive T-cell therapies in melanoma.

oncology
Exploring Staging, Prognosis, and Treatment Innovations

Walid Shalata,Zoe Gabrielle Attal,Adam Solomon,Sondos Shalata,Omar Abu Saleh,Lena Tourkey,Fahed Abu Salamah,Ibrahim Alatawneh,Alexander Yakobson

DOI: https://doi.org/10.3390/ijms25115794

IF: 5.6

2024-05-27

International Journal of Molecular Sciences

Abstract:Melanoma, a malignant neoplasm originating from melanocytes, stands as one of the most prevalent cancers globally, ranking fifth in terms of estimated new cases in recent years. Its aggressive nature and propensity for metastasis pose significant challenges in oncology. Recent advancements have led to a notable shift towards targeted therapies, driven by a deeper understanding of cutaneous tumor pathogenesis. Immunotherapy and tyrosine kinase inhibitors have emerged as promising strategies, demonstrating the potential to improve clinical outcomes across all disease stages, including neoadjuvant, adjuvant, and metastatic settings. Notably, there has been a groundbreaking development in the treatment of brain metastasis, historically associated with poor prognosis in oncology but showcasing impressive results in melanoma patients. This review article provides a comprehensive synthesis of the most recent knowledge on staging and prognostic factors while highlighting emerging therapeutic modalities, with a particular focus on neoadjuvant and adjuvant strategies, notably immunotherapy and targeted therapies, including the ongoing trials.

biochemistry & molecular biology,chemistry, multidisciplinary

Systems biology of IL-6, IL-12 family cytokines.

Adjuvant immunotherapy for melanoma patients: progress and opportunities

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Changing the Future As We Prepare for a New Millennium

ORGANO-NITROGEN COMPOUNDS FROM MOLECULAR NITROGEN

Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

The Relation between Five-Factor Personality Traits and Risk-Taking Behavior in Preadolescents

Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care

Current Advances in the Treatment of BRAF-Mutant Melanoma

Neoadjuvant therapy for resectable melanoma

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Precision Oncology in Melanoma: Changing Practices

Therapeutic options in cutaneous melanoma: latest developments

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Advances in the discovery and development of melanoma drug therapies

Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View

Neoadjuvant Therapy in Advanced Melanoma.

Dynamical Jahn-Teller effect and fluorescence line narrowing of the 4A2-4T2 zero-phonon transition in KZnF3:Cr.

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Exploring Staging, Prognosis, and Treatment Innovations